Investors Research Corp Adaptimmune Therapeutics PLC Call Options Transaction History

Investors Research Corp

  • $441 Million
  • Q4 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $37.6M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Investors Research Corp Portfolio

Follow Investors Research Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Investors Research Corp, based on Form 13F filings with the SEC.

News

Stay updated on Investors Research Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email